Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
Globe Newswire•05/10/2026•08:45 ET
9
Key Highlights
- ➤Immix Biopharma to present at 45th Annual J.P. Morgan Healthcare Conference, January 11-14, 2027
- ➤NXC-201 is being evaluated in potentially registrational NEXICART-2 study for relapsed/refractory AL Amyloidosis
- ➤NXC-201 received FDA Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations
- ➤NXC-201 holds FDA and EU EMA Orphan Drug Designations
LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.
A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.
Get started
Create a free account to read the full story.